SLC5A2 and alcoholic fatty liver disease: As to implications for practice and policy, the positive evidence from this meta-analysis considers the use of SGLT-2 inhibitors for the treatment of Type 2 diabetes mellitus with an obese profile in the setting of concomitant non-alcoholic fatty liver disease.